Discovery of Potent Vascular Endothelial Growth Factor Receptor-2 Inhibitors

被引:11
|
作者
Papakyriakou, Athanasios [1 ]
Katsarou, Maria E. [1 ]
Belimezi, Maria [2 ]
Karpusas, Michael [3 ]
Vourloumis, Dionisios [1 ]
机构
[1] NCSR Demokritos, Lab Chem Biol Nat Prod & Designed Mol, Inst Phys Chem, Athens 15310, Greece
[2] Regulon AE, Athens 17455, Greece
[3] Agr Univ Athens, Phys Lab, Dept Sci, Athens 11855, Greece
关键词
angiogenesis; drug design; inhibitors; medicinal chemistry; molecular dynamics; VEGFR-2; TYROSINE KINASE INHIBITORS; TUMOR-DRIVEN ANGIOGENESIS; AMBER FORCE-FIELD; CLINICAL DEVELOPMENT; MOLECULAR-DYNAMICS; PROTEIN-KINASES; VEGF; DESIGN; TARGET; BIOLOGY;
D O I
10.1002/cmdc.200900373
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Substantial evidence over the last decades has implicated uncontrolled angiogenesis with various pathological states, including cancer. Vascular endothelial growth factor (VEGF) plays a critical role in its regulation. Because the tyrosine kinase VEGF receptor-2 (VEGFR-2) is the major mediator of the mitogenic, angiogenic, and permeability-enhancing effects of VEGF, it has become one of the most profound anti-angiogenesis targets. Inspired by the anthranilamide class of VEGFR-2 inhibitors, we performed a computational analysis of some potent representative members, using docking and molecular dynamics calculations. Based on the observations drawn from introducing the effect of the receptor's flexibility in implicit aqueous environment, we designed, synthesized, and characterized several new analogues of related scaffolds with modifications in their steric and electronic characteristics. In vitro evaluation of these compounds revealed several novel VEGFR-2 inhibitors that are less cytotoxic and more potent than the parent compounds.
引用
收藏
页码:118 / 129
页数:12
相关论文
共 50 条
  • [1] Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors
    Kuo, GH
    Wang, AH
    Emanuel, S
    DeAngelis, A
    Zhang, R
    Connolly, PJ
    Murray, WV
    Gruninger, RH
    Sechler, J
    Fuentes-Pesquera, A
    Johnson, D
    Middleton, SA
    Jolliffe, L
    Chen, X
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (06) : 1886 - 1900
  • [2] Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors
    Weiss, Matthew M.
    Harmange, Jean-Christophe
    Polverino, Anthony J.
    Bauer, David
    Berry, Loren
    Berry, Virginia
    Borg, George
    Bready, James
    Chen, Danlin
    Choquette, Deborah
    Coxon, Angela
    DeMelfi, Tom
    Doerr, Nicholas
    Estrada, Juan
    Flynn, Julie
    Graceffa, Russell F.
    Harriman, Shawn P.
    Kaufman, Stephen
    La, Daniel S.
    Long, Alexander
    Neervannan, Sesha
    Patel, Vinod F.
    Potashman, Michele
    Regal, Kelly
    Roveto, Phillip M.
    Schrag, Michael L.
    Starnes, Charlie
    Tasker, Andrew
    Teffera, Yohannes
    Whittington, Douglas A.
    Zanon, Roger
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (06) : 1668 - 1680
  • [3] Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors.
    Kuo, GH
    Wang, AH
    Emanuel, S
    DeAngelis, A
    Zhang, R
    Connolly, PJ
    Murray, WV
    Gruninger, RH
    Sechler, J
    Fuentes-Pesquera, A
    Johnson, D
    Middleton, SA
    Jolliffe, L
    Chen, X
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U950 - U950
  • [4] Vascular endothelial growth factor receptor-2 in breast cancer
    Guo, Shanchun
    Colbert, Laronna S.
    Fuller, Miles
    Zhang, Yuanyuan
    Gonzalez-Perez, Ruben R.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2010, 1806 (01): : 108 - 121
  • [5] Vascular endothelial growth factor and vascular endothelial growth factor receptor-2 expression in mdx mouse brain
    Nico, B
    Corsi, P
    Vacca, A
    Roncali, L
    Ribatti, D
    [J]. BRAIN RESEARCH, 2002, 953 (1-2) : 12 - 16
  • [6] Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor
    Xie, Chengying
    Wan, Xiaozhe
    Quan, Haitian
    Zheng, Mingyue
    Fu, Li
    Li, Yun
    Lou, Liguang
    [J]. CANCER SCIENCE, 2018, 109 (04): : 1207 - 1219
  • [7] Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Expression in the Chick Embryo Area Vasculosa
    Beatrice Nico
    Angelo Vacca
    Michela De Giorgis
    Luisa Roncali
    Domenico Ribatti
    [J]. The Histochemical Journal, 2001, 33 : 283 - 286
  • [8] Vascular endothelial growth factor and vascular endothelial growth factor receptor-2 expression in the chick embryo area vasculosa
    Nico, B
    Vacca, A
    De Giorgis, M
    Roncali, L
    Ribatti, D
    [J]. HISTOCHEMICAL JOURNAL, 2001, 33 (05): : 283 - 286
  • [9] MAb against vascular endothelial growth factor receptor-2 (KDR)
    Basalp, Aynur
    Yucel, Fatima
    Kumbasar, Asli
    Baysal, Kemal
    [J]. HYBRIDOMA, 2006, 25 (04): : 248 - 249
  • [10] Discovery of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors by Ligand-based Virtual High Throughput Screening
    Chelliah, Selvam
    Mock, Charlotta D.
    Mathew, Omana P.
    Ranganna, Kasturi
    [J]. FASEB JOURNAL, 2018, 32 (01):